Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

References

• PariserDMBagelJGelfandJMNational Psoriasis Foundation clinical consensus on disease severityArch Dermatol2007143223924217310004
   PubMed Web of Science ®Google Scholar
• CallenJPKruegerGGLebwohlMAAD consensus statement on psoriasis therapiesJ Am Acad Dermatol200349589789914576671
   PubMed Web of Science ®Google Scholar
• GudjonssonJEElderJTPsoriasis: EpidemiologyClin Dermatol200725653554618021890
   PubMed Web of Science ®Google Scholar
• de KorteJSprangersMAMombersFMBosJDQuality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc200492140147
   PubMed Web of Science ®Google Scholar
• KimballABGladmanDGelfandJMNational Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningJ Am Acad Dermatol20085861031104218313171
   PubMed Web of Science ®Google Scholar
• FeldmanSRPearceDJManagement and costs of severe psoriasis: The role of new biologicsExpert Rev Pharmacoecon Outcomes Res20044557357919807550
   PubMedGoogle Scholar
• DriessenRJBisschopsLAAdangEMEversAWvan de KerkhofPCMde JongEMThe economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologicsBr J Dermatol201016261324132920163420
   PubMed Web of Science ®Google Scholar
• ReichKSchenkelBZhaoNUstekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2J Dermatolog Treat201122633734721034290
   PubMed Web of Science ®Google Scholar
• Jones-CaballeroMUnaezeJPenasPFSternRSUse of biological agents in patients with moderate to severe psoriasisArch Dermatol2007143784685017638727
   PubMedGoogle Scholar
• KruegerGKooJLebwohlASternRSRolstadTThe impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol2001137328028411255325
   PubMed Web of Science ®Google Scholar
• FinlayAYOrtonneJPPatient satisfaction with psoriasis therapies: an update and introduction to biologic therapyJ Cutan Med Surg20048531032015868312
   PubMed Web of Science ®Google Scholar
• RichardsHLFortuneDGO’SullivanTMMainCJGriffithsCEPatients with psoriasis and their compliance with medicationJ Am Acad Dermatol199941458158310495380
   PubMed Web of Science ®Google Scholar
• ChristophersESegaertSMilliganGMoltaCTBoggsRClinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: Results of a European cross-sectional observational studyJ Dermatolog Treat Epub May 23, 2012
   Web of Science ®Google Scholar
• LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med2012366131190119922455413
   PubMed Web of Science ®Google Scholar
• LangrishCLChenYBlumenscheinWMIL-23 drives a pathogenic T cell population that induces autoimmune inflammationJ Exp Med2005201223324015657292
   PubMed Web of Science ®Google Scholar
• HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol20056111123113216200070
   PubMed Web of Science ®Google Scholar
• LowesMAKikuchiTFuentes-DuculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol200812851207121118200064
   PubMed Web of Science ®Google Scholar
• YilmazSBCicekNCoskunMYeginOAlpsoyESerum and tissue levels of IL-17 in different clinical subtypes of psoriasisArch Dermatol Res2012304646546922426986
   PubMed Web of Science ®Google Scholar
• ChiricozziAGuttman-YasskyESuarez-FarinasMIntegrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasisJ Invest Dermatol2011131367768721085185
   PubMed Web of Science ®Google Scholar
• HueberWPatelDDDryjaTEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72
   PubMed Web of Science ®Google Scholar
• KruegerJGFretzinSSuarez-FarinasMIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJ Allergy Clin Immunol2012130114515422677045
   PubMed Web of Science ®Google Scholar
• MartinDATowneJEKricorianGThe emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findingsJ Invest Dermatol Epub June 7, 2012
   Web of Science ®Google Scholar
• ZabaLCSuarez-FarinasMFurentes-DuculanJEffective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJ Allergy Clin Immunol200912451022103019895991
   PubMed Web of Science ®Google Scholar
• AjujlaSJChanYRZhengMIL-22 mediates mucosal host defense against gram-negative bacterial pneumoniaNat Med200814327528118264110
   PubMed Web of Science ®Google Scholar
• HuangWNaLFidelPLSchwarzenbergerPRequirement of inter-leukin-17A for systemic anti-Candida albicans host defense in miceJ Infect Dis2004190362463115243941
   PubMed Web of Science ®Google Scholar
• ReichKAnti-interleukin-17 monoclonal antibody ixekizumab in psoriasisN Engl J Med2012367327422808966
   PubMed Web of Science ®Google Scholar
• HerrierRNAdvances in the treatment of moderate-to-severe plaque psoriasisAm J Health Syst Pharm201168979580621515863
   PubMed Web of Science ®Google Scholar
• ReichKBurdenADEatonJNHawkinsNSEfficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBr J Dermatol2012166117918821910698
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol2003139121627163214676082
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trialLancet200536694941367137416226614
   PubMed Web of Science ®Google Scholar
• HsuSPappKALebwohlMGConsensus guidelines for the management of plaque psoriasisArch Dermatol201214819510222250239
   PubMedGoogle Scholar
• LangleyRGStroberBEGuYRozzoSJOkunMMBenefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasisBr J Dermatol201016261349135820394634
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleu-kin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med2007356658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• RallisEVerrosCDUstekinumab treats psoriasis refractory to seven conventional and biologic therapiesDermatol Online J20111741421549089
   PubMedGoogle Scholar
• GriffithsCEStroberBEvan de KerkhofPComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med2010362211812820071701
   PubMed Web of Science ®Google Scholar
• MarjiJSMarcusRMoennichJMackay-WigganJUse of biologic agents in pediatric psoriasisJ Drugs Dermatol20109897598620684148
   PubMed Web of Science ®Google Scholar
• FerrandizCGarciaABlascoAJLazaroPCost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasisJ Eur Acad Dermatol Venereol201226676877722126264
   PubMed Web of Science ®Google Scholar
• NelsonAAPearceDJFleischerABJrBalkrishnanRFeldmanSRCost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJ Am Acad Dermatol200858112513517996329
   PubMed Web of Science ®Google Scholar